Does stronger preliminary response to most cancers remedy predict longer total survival?

It seems like such a simple question: Do patients whose tumors shrink more in response to targeted treatment go on to have better outcomes than patients whose tumors shrink less? But the implications of a recent study demonstrating this relationship are anything but simple and could influence both the design of future clinical trials and the goals of oncologists treating cancer.